• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Physical disability and psychological distress demonstrate marked progression after diagnosis of cancer

byJayden BerdugoandAlex Chan
August 27, 2025
in Chronic Disease, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this Australian cohort of adults, individuals diagnosed with cancer experienced greater declines in physical functioning and slightly higher psychological distress compared to people without cancer

2. This finding was especially pronounced among those with advanced disease or recent treatment. 

Evidence Rating Level: 1 (Excellent) 

Cancer survival rates are improving worldwide due to better early detection and treatment. In Australia, the 5-year survival rate for all cancers rose from 50.2% in 1989-1993 to 70.6% in 2015-2019. While cancer survivors are generally more likely to experience physical limitations and mild psychological distress, outcomes vary widely by cancer type, stage, and treatment status. Previous research has been limited by short follow-up periods, a focus on single cancer types, and a lack of pre-diagnosis data or control groups without cancer. This study addresses those gaps by using large-scale, population-based data to compare physical and psychological changes from before to after cancer diagnosis with matched changes in people without cancer. After removing ineligible individuals who had cancer at baseline, the main focus was on those who were newly diagnosed with cancer between the first and follow-up surveys. The primary outcomes were how much physical limitations (assessed using the Medical Outcomes Study Physical Functioning [MOS-PF] score) and psychological distress (assessed using the Kessler-10 [K10]) changed between baseline to follow-up. After meeting eligibility criteria, 142,682 participants were included in the study. Over 5.2 years, 9,313 participants were diagnosed with cancer while 133,369 were not. Participants diagnosed with cancer experienced a greater deterioration in physical function over time compared to those without cancer (40.6% vs. 52.3%). Compared to people without cancer, cancer survivors had larger declines in physical functioning (average follow-up score: 77.5 vs 82.9; average change: -8.31 vs -4.71; adjusted difference -2.55, 95% CI: -2.97 to -2.13) and slightly more psychological distress (average follow-up score: 13.6 versus 13.5 at follow-up; mean-change: 0.24 versus − 0.04; adjusted-difference 0.21 (95%CI = 0.12–0.31)). Physical health declined more for people with multiple myeloma, lung cancer, and leukemia, and less for those with breast, colorectal, or prostate cancer. Survivors with advanced disease or those still undergoing treatment experienced greater declines in physical and psychological well-being. However, psychological well-being was similar between cancer-free individuals and survivors who were not receiving treatment at follow-up. In conclusion, participants newly diagnosed with cancer experienced a significantly greater decline in physical function and slightly decreased psychological well-being compared to participants without cancer. 

Click to read the study in BMC Medicine

Image: PD

RELATED REPORTS

Pfizer’s Talzenna combo significantly delays prostate cancer progression

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

Dipeptidyl peptidase-4 inhibitors may be associated with an increased incidence of malignancy

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cancerchronic diseasemedical oncologyoncologypsychiatry
Previous Post

Oral gepotidacin is non-inferior to standard therapy for uncomplicated urogenital gonorrhea

Next Post

Artificial Intelligence Model Matches Patients to Clinical Trials with Near Human Accuracy

RelatedReports

Radiation plus hormone therapy may improve prostate cancer survival
Oncology

Pfizer’s Talzenna combo significantly delays prostate cancer progression

April 1, 2026
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Endocrinology

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

March 30, 2026
Intrapartum serum prolactin may predict risk of postpartum diabetes
Chronic Disease

Dipeptidyl peptidase-4 inhibitors may be associated with an increased incidence of malignancy

March 26, 2026
High frequency of germline mutations observed in triple negative breast cancers
The Scan by 2 Minute Medicine®

Susie Wiles’ breast cancer diagnosis drives national screening surge

March 25, 2026
Next Post
Anaerobic antibiotics may decrease mortality in infants with necrotizing enterocolitis

Artificial Intelligence Model Matches Patients to Clinical Trials with Near Human Accuracy

Increased number of daily steps linked with decreased mortality in older women

Semaglutide improves walking ability in patients with peripheral artery disease and type 2 diabetes

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors

Pulsed field ablation noninferior to cryoablation for reducing paroxysmal atrial fibrillation recurrence

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early surgical valve replacement offers survival benefit in asymptomatic, very severe aortic stenosis
  • Atopic dermatitis activity is not associated with cardiovascular risk
  • Zorevunersen appears safe and may alleviate symptoms in children with Dravet syndrome
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

The Classics in Medicine Paperback Released!

Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. In response, 2 Minute Medicine presents 160+ authoritative, physician-written summaries of the most cited landmark trials in medicine.

amazon-logo_blackGet-it-on-iBooks-badge

Click anywhere to close this announcement

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.